Dr. Bai Zhonghu (professor and Ph.D. supervisor) graduated from the department of chemical engineering, Zhejiang University in 1987, graduated from the department of chemical engineering, Tsinghua University in 1992 and received Ph.D. in biology from University of Strathclyde in 2002. From 2002 to 2005, he completed postdoctoral research in Oxford University and ICSTM. From 2005 to 2012, he successively engaged in the research and development of clinical immunological analysis and diagnosis technology in Johnson & Johnson, UK, and engaged in therapeutic antibody pharmaceutical process engineering in the biomedical research center of GSK, UK , serving as senior researcher and principal investigator respectively. In 2010, he was selected into the third batch of thousand talents plan (long-term technical innovation) of the Organization Department of the Central Committee of the CPC. In 2012, he was selected as one of Jiangsu Innovative and Entrepreneurial Talents, and in 2013, he was selected as the leading talent of Jiangsu Innovative and Entrepreneurial Talent team, and in 2016, he was selected into Shandong Mount Tai talent plan.

In September 2012, he returned to China, established Jiangsu Baiming Biotechnology Company Limited and mainly engaged in the innovation and development of clinical immunological analysis technology products. At the same time, he joined the national fermentation engineering laboratory of Jiangnan University as a professor and a doctoral supervisor. Dr. Bai has nearly 20 years of research and development experience in international first-class companies and domestic leading enterprises in the field of biomedical technology, and is familiar with international rules in relevant fields. In his early career, he participated in the establishment and development of two domestic biotechnology companies, one of which was listed on the main board (in 2016) and the other was acquired by a famous listed pharmaceutical company (in 2014).

After returning to China, Dr. Bai has received two national 863 project (project leader) and one 973 project (core backbone). He has published more than 20 papers on SCI in the past three years and obtained more than 10 national invention patents.

He participated in the demonstration of the development planning of emerging industries for NDRC’s 13th-Five-Year Plan .Since 2016, he has been the chief biomedical scientist of SHINVA (listed company). The Jiangsu Baiming Biotechnology Company Limited founded by Dr. Bai has completed the development and CFDA registration of China’s leading and internationally advanced fully automatic clinical immune diagnostic product series. The company has completed two rounds of venture capital (totaling 40 million yuan). The product has went into the market in the first half of 2018.

Jiangsu Baiming Biotechnology Company Limited and Collaborative Innovation Center of Jiangnan University are currently cooperating with China Agricultural Vet. Bio. Science and Technolog Co., Ltd  to develop chemiluminescent immunoassay technology products for animal diseases such as foot-and-mouth disease. Two national invention patents have been applied. The technology has significantly innovated the current diagnosis method of foot-and-mouth disease, It can shorten the analysis and detection time from 2 days to 2 hours and can realize high throughput and automation.

How should the manufacturers of biopharmaceutical equipment meet the challenges from dynamic development of life science

Innovative biomedicine is an important strategic emerging industry in China. With the basic research of life science and the development of biotechnology in the past 20 years, the biomedical industry in the word has maintained a rapid growth. For instance, the therapeutic antibody industry using CHO cell culture as the core production technology has developed from $1 billion in 2000 to $70 billion today. The 2017 is the first year of the development of the clinical application of cellular immunotherapy represented by CAR-T, and it is predicted that in the next 5-10 years, the biomedical industry with individualized cell culture as the core production technology will also break through hundreds of billions of dollars. Gene therapy based on gene-editing technology and clinical application of stem cells will also become a common method of clinical treatment in the near future. The emergence of these new treatment technologies has accelerated the revolutionary changes in the technology and concept of biological medicine production, and has also brought forth many new market requirements and technical challenges to the traditional pharmaceutical equipment industry.  As early as possible, equipment manufacturers should actively participate in the clinical experiment and application of new treatment technology and actively participate in the formulation of clinical application, production process and quality control standards at national level. If Chinese pharmaceutical equipment enterprises could positively face the challenges of biomedical equipment and new technology brought about by the progress of life science, they will be in good position to seize the opportunities of industrial development and then to complete the upgrading of the industry smoothly. At the same time, it can effectively promote the healthy development of the new bio pharmaceutical industry in China, and realize the new biological medicine technology as the "civilian" treatment means for the public.